Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering a novel therapeutic approach known as immuno-neurology. The company leverages the body’s innate immune system to develop treatments for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). Alector’s groundbreaking research focuses on counteracting brain pathologies by restoring healthy immune function.
The company’s pipeline includes several promising product candidates like AL001 (latozinemab), AL002, AL003, and AL101. Among these, latozinemab and AL101 are being co-developed in collaboration with global biopharmaceutical giant GSK. Latozinemab, a progranulin-elevating monoclonal antibody, is currently in the pivotal Phase 3 INFRONT-3 trial for FTD-GRN and has received FDA Breakthrough Therapy and Fast Track designations.
AL002, in collaboration with AbbVie, is a TREM2-activating antibody undergoing a Phase 2 INVOKE-2 trial to assess its efficacy in early Alzheimer's disease. The company recently completed enrollment for INVOKE-2, with a data readout expected in the fourth quarter of 2024. AL101, another progranulin-elevating candidate, has initiated the PROGRESS-AD Phase 2 trial to treat early Alzheimer's disease.
Alector’s innovative Alector Brain Carrier (ABC) technology aims to enhance drug delivery across the blood-brain barrier, further strengthening their therapeutic pipeline. The company’s financial health is robust, with $620.0 million in cash, cash equivalents, and investments as of January 2024. This financial buffer is anticipated to fund operations through 2026, ensuring continued progress in their clinical programs.
For ongoing updates and detailed information, visit their official website at www.alector.com.
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
What is Alector, Inc. known for?
What are the main product candidates in Alector's pipeline?
What recent achievements has Alector accomplished?
Who are Alector's key collaborators?
What is the focus of Alector's immuno-neurology approach?
When is the data readout for the INVOKE-2 trial expected?
What is the Alector Brain Carrier (ABC) technology?
What financial condition is Alector currently in?
What is the significance of the FDA Breakthrough Therapy Designation for latozinemab?
Where can more information about Alector be found?
